Clinical trial

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

Opening soon · Not applicable · 1 countries · Registry ID NCT07423481

Opening soonNot applicableObservational

What this study is about

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionObesity & Overweight

Full registry criteria

Inclusion Criteria: * Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY * No objection to the use of their data * Patients able to complete an online questionnaire (via the internet) Exclusion Criteria: • Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection

Treatments and study arms

SEMAFOLLOW questionnaire

Other

If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes

Primary outcomes

Describe weight changes during the follow-up period according to patient characteristics.Baseline

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Nantes university hospital🇫🇷 Nantes, France

Open map

David JACOBIContact

Email · Call +33253482709